Adapalene/benzoyl peroxide
Combination of
AdapaleneRetinoid
Benzoyl peroxidePeroxide
Clinical data
Trade namesEpiduo, Epiduo Forte
Routes of
administration		Topical
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG
 ☒NcheckY (what is this?)  (verify)

Adapalene/benzoyl peroxide, sold under the brand name Epiduo among others, is a fixed-dose combination medication for the treatment of severe acne vulgaris.[1][2] It consists of a combination of adapalene and benzoyl peroxide in a topical gel formulation.[1][2]

It is available as a generic medication.[3]

Medical uses

Adapalene/benzoyl peroxide is indicated for the topical treatment of acne vulgaris.[1][2]

Side effects

Commonly reported side effects include the following:[1][2]

Research

Meta-analysis of clinical trials has shown this combined therapy to be more effective than either of its ingredients by themselves.[4]

The use of adapalene/benzoyl peroxide in combination with oral antibiotics (lymecycline) has been studied;[5] the combination was well tolerated and showed an improved success rate compared to those receiving only antibiotics (47.6% vs. 33.7%, P = 0.002).

References

  1. ^ a b c d e "Epiduo- adapalene and benzoyl peroxide gel". DailyMed. 21 February 2018. Retrieved 15 May 2022.
  2. ^ a b c d e "Epiduo Forte- adapalene and benzoyl peroxide gel". DailyMed. 27 April 2022. Retrieved 15 May 2022.
  3. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  4. ^ Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS (August 2011). "Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients". The Journal of Dermatological Treatment. 22 (4): 197–205. doi:10.3109/09546631003681094. PMID 20666678. S2CID 34631151.
  5. ^ Dréno B, Kaufmann R, Talarico S, Torres Lozada V, Rodríguez-Castellanos MA, Gómez-Flores M, et al. (August 2011). "Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study". The British Journal of Dermatology. 165 (2): 383–90. doi:10.1111/j.1365-2133.2011.10374.x. PMID 21495995. S2CID 21793660.

External links

Nestlé
Acne-treating agents (D10)
More
Categories